Open Life SciencesPub Date : 2025-07-18eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1140
Ying Wu, Xue-Ying Li, Jin-Dong Chen, You-Fu Pan
{"title":"BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells.","authors":"Ying Wu, Xue-Ying Li, Jin-Dong Chen, You-Fu Pan","doi":"10.1515/biol-2025-1140","DOIUrl":"10.1515/biol-2025-1140","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. A few genes, such as <i>BAP1</i>, are associated with the tumorigenesis of ccRCC. Mutations in <i>BAP1</i> are related to a proportion of ccRCCs. In this study, to explore the functional role of <i>BAP1</i> in ccRCC, the potential interacting proteins with <i>BAP1</i> in ccRCC cells are to be identified, and the gene expression profiles of <i>BAP1</i> knockdown 786-O cells are to be analyzed.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251140"},"PeriodicalIF":1.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-18eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1136
Anna Andreadi, Evgenia Tsivelekidou, Iasonas Dermitzakis, Paschalis Theotokis, Sofia Gargani, Soultana Meditskou, Maria Eleni Manthou
{"title":"Innovations in MALDI-TOF Mass Spectrometry: Bridging modern diagnostics and historical insights.","authors":"Anna Andreadi, Evgenia Tsivelekidou, Iasonas Dermitzakis, Paschalis Theotokis, Sofia Gargani, Soultana Meditskou, Maria Eleni Manthou","doi":"10.1515/biol-2025-1136","DOIUrl":"10.1515/biol-2025-1136","url":null,"abstract":"<p><p>Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a robust analytical technology that has become integral to biomolecular research. Since its introduction into microbiology in the early 2000s, its versatility has enabled a wide spectrum of applications extending from routine microbial identification to advanced proteomic profiling, antimicrobial resistance testing, biomarker discovery, and even historical disease investigation. In proteomics, MALDI-TOF MS has proven valuable for identifying disease-associated proteins, with applications in oncology, metabolic disorders such as diabetes and dyslipidemia, neurodegenerative diseases, hemoglobinopathies, and neonatal screening. Additionally, it has facilitated pharmacokinetic studies by enabling detailed analysis of drug distribution and metabolism. Despite limitations such as dependency on reference databases and challenges in distinguishing closely related species, ongoing advancements continue to enhance its accuracy and range. The integration of MALDI-TOF MS with molecular methods like polymerase chain reaction further strengthens its diagnostic utility. This review aims to present recent technological progress while highlighting the expanding interdisciplinary utility of MALDI-TOF MS. Emphasis is placed on emerging fields, including paleopathology, where its potential remains underexploited. By outlining its evolving capabilities, we propose a conceptual framework that positions MALDI-TOF MS as a unifying platform capable of driving innovation across diverse scientific and biomedical disciplines.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251136"},"PeriodicalIF":1.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-18eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1112
Alexander Darmonkow, Zoë E M Rowe, Scott V Harding
{"title":"Advancements in curcuminoid formulations: An update on bioavailability enhancement strategies curcuminoid bioavailability and formulations.","authors":"Alexander Darmonkow, Zoë E M Rowe, Scott V Harding","doi":"10.1515/biol-2025-1112","DOIUrl":"10.1515/biol-2025-1112","url":null,"abstract":"<p><p>Here, we provide a current review of strategies aimed at improving the bioavailability of curcuminoids, a group of compounds with therapeutic potential. This review discusses formulations from the traditional supplementation approaches to the innovative methods to enhance solubility and bioavailability, including cyclodextrins and hydrophilic carriers. Additionally, colloidal delivery strategies, such as micelles, liposomes, solid lipid particles, and emulsions, are examined as promising vehicles for curcuminoid delivery. The review underscores the importance of clinical trials in assessing the efficacy of these formulations and highlights a pivotal yet frequently neglected factor in curcuminoid research: the differentiation between total and free curcuminoid quantification. In summary, this concise review evaluates existing curcuminoid formulations and explores innovative approaches to improve their bioavailability.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251112"},"PeriodicalIF":1.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-15eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1113
Yingying Li, Hui Tang, Xiangjun Yang, Nan Men
{"title":"The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients.","authors":"Yingying Li, Hui Tang, Xiangjun Yang, Nan Men","doi":"10.1515/biol-2025-1113","DOIUrl":"10.1515/biol-2025-1113","url":null,"abstract":"<p><p>Breast cancer (BC) is a common malignant tumor with a frequent occurrence in women, and its occurrence and progression are influenced by various factors. This work aimed to investigate the expression of human epidermal growth factor receptor-2 (HER-2) in BC and its relationship with tumor-infiltrating lymphocytes (TILs) and the clinical pathological features of BC patients. Data from 470 BC patients were collected, and TIL levels were assessed. Immunohistochemistry (IHC) was performed to further analyze the relationship between TILs and clinical pathological parameters, as well as the expression of CD8 and HER-2. Immunohistochemical results revealed that the HER-2-positive expression rate was 28.72% (135/470), and its expression intensity significantly increased with higher histological grades (low grade: 15.2%, moderate grade: 28.5%, high grade: 42.6%, <i>P</i> < 0.05). CD8-positive cells were predominantly located in the tumor stroma, with a positive rate of 56.38% (265/470). Moreover, the positive expression intensity in the high TIL level group was significantly higher than in the low TIL level group (high TIL group: 78.9%, low TIL group: 35.4%, <i>P</i> < 0.05). The statistical results indicated that 37.45% (176/470) of cases exhibited no or low TIL levels, 42.34% (199/470) showed moderate TIL levels, and 20.21% (95/470) presented high TIL levels. TIL levels were significantly associated with histological grade of BC (percentage of high-grade cases in the high TIL group: 65.3%, in the low TIL group: 22.1%, <i>P</i> < 0.05), Ki-67 index (high TIL group: 45.2% ± 12.3%, low TIL group: 25.6% ± 10.8%, <i>P</i> < 0.05), vascular tumor embolism (VTE) (VTE-positive rate in the high TIL group: 38.9%, in the low TIL group: 12.4%, <i>P</i> < 0.05), lymph node metastasis (LNM) (LNM-positive rate in the high TIL group: 52.6%, in the low TIL group: 28.4%, <i>P</i> < 0.05), and estrogen receptor (ER) expression (ER-negative rate in the high TIL group: 68.4%, in the low TIL group: 32.1%, <i>P</i> < 0.05). Spearman correlation analysis revealed a positive correlation between TILs and HER-2 (<i>r</i> = 0.149, <i>P</i> = 0.002), as well as CD8 (<i>r</i> = 0.593, <i>P</i> = 0.001). Analysis of the GEPIA database showed that patients with high HER-2 expression had significantly lower disease-free survival (DFS) compared to those with low expression (hazard ratio [HR] = 1.45, <i>P</i> = 0.003), while patients with high CD8 expression exhibited significantly higher DFS than those with low expression (HR = 0.72, <i>P</i> = 0.001). In HER-2-positive BC patients, TIL levels were positively correlated with HER-2 and CD8 expression (high HER-2 expression group: TIL high expression rate 48.6%, low HER-2 expression group: TIL high expression rate 15.2%, <i>P</i> < 0.05). TIL levels in HER-2-positive BC patients were positively correlated with both HER-2 and CD8 expression. TIL levels were closely related to the prognosis of BC patients, which may provide a theoreti","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251113"},"PeriodicalIF":1.7,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-15eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1072
Latifa AlHusnain, Atef Shahin, Farid Mehiar, Kotb A Attia, Mohamed Eid, Yaser Hafez, Nadi A Al-Harbi, Khaled Abdelaal
{"title":"Heritability of durable resistance to stripe rust in bread wheat (<i>Triticum aestivum</i> L.).","authors":"Latifa AlHusnain, Atef Shahin, Farid Mehiar, Kotb A Attia, Mohamed Eid, Yaser Hafez, Nadi A Al-Harbi, Khaled Abdelaal","doi":"10.1515/biol-2025-1072","DOIUrl":"10.1515/biol-2025-1072","url":null,"abstract":"<p><p>Wheat yellow (stripe) rust is one of the most destructive diseases worldwide. Growing resistant cultivars is the most economical and eco-friendly method to control the disease. To determine heritability and gene number of durable resistance to stripe rust, four Egyptian wheat cultivars were crossed to four genotypes; Jupateco 73R, Opata 85, Anza, and Pavon 76 carrying the durable resistant genes were studied to enhance wheat yellow rust durable resistance. The genetic analysis has been done based on F<sub>1</sub>, and F<sub>2</sub> of crosses, and our findings confirmed the di-genic and tri-genic control to this disease. The result from the F<sub>2</sub> population showed that Misr2/Opata and Giza168/Anza were segregated fitting the expected ratios of 57 resistant: 7 susceptible. The segregation ratios of resistance and susceptibility of F<sub>2</sub> plants showed tri-genic hereditary of yellow rust resistance, permitting the following conclusions about the genes expressed in adult plants suggesting a difference of three dominant genes between the parental cultivars. The cross Giza168/Pavon76 was showed phenotypic ratios fitted the theoretical ratios, 63 resistant: 1 susceptible, suggesting difference of two dominant and one recessive gene for resistance. These genotypes are very important for wheat breeding to stripe rust resistance in Egypt.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251072"},"PeriodicalIF":1.7,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-11eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1124
Rim Ben Mansour, Hanen Falleh, Majdi Hammami, Feriel Ben Hadid, Lilian Barros, Neji Tarchoun, Spyridon A Petropoulos, Riadh Ksouri
{"title":"Optimizing the encapsulation of the refined extract of squash peels for functional food applications: A sustainable approach to reduce food waste.","authors":"Rim Ben Mansour, Hanen Falleh, Majdi Hammami, Feriel Ben Hadid, Lilian Barros, Neji Tarchoun, Spyridon A Petropoulos, Riadh Ksouri","doi":"10.1515/biol-2025-1124","DOIUrl":"10.1515/biol-2025-1124","url":null,"abstract":"<p><p>Encapsulation of the refined extract from squash fruit peels was evaluated for the design of functional foods with beneficial effects on human health. The percentage of maltodextrin and gum Arabic in the wall material as well as the concentration of the refined extract were the independent variables for the Box Behnken design, and their impact on response variables (total phenolic compound [TPC] content, DPPH activity, the size of particles, and polydispersity index [Pdi]) was evaluated. The obtained emulsions were compared based on their TPC content, as well as their antioxidant activities. Optimum conditions were as follows: maltodextrin percentage of 23.8%, gum Arabic percentage of 27.7%, and phenolic extract percentage of 48.5%. Under these conditions, the response variables were the following: TPC content of 46.01 mg of gallic acid equivalent per gram of extract (mg GAE/g of E); DPPH inhibition percentage of 64.85% at 1 mg/mL, particle size of 571.22 nm, and Pdi of 0.46. Once the emulsion was optimized, we tried to define the combination of variables that produced microcapsules with the highest TPC content and the highest antioxidant activity. Physicochemical parameters and biological activities were also assessed. Microcapsule parameters were a pH of 4.2, a viscosity of 17 mPa/s, and a turbidity of 0.412 NTU (Nephelometric Turbidity Units), and color measurements were <i>L</i> = 102.4, <i>a</i> = 3.5, and <i>b</i> = 7.8. Indeed, the TPC content was 37.2 mg GAE/g dried residue and antiradical activity against DPPH was 44.2%. The inhibitory effects of the optimized emulsion on <i>Enterococcus faecalis</i>, <i>Pseudomonas aeruginosa</i>, <i>Salmonella typhimurium</i>, and <i>Staphylococcus aureus</i> were investigated, and the results indicated the highest sensitivity (89% inhibition) for <i>S. typhimurium</i>. Our results indicate the efficiency of the optimized emulsification process for developing microcapsules of high quality as well as the potential of using them in the development of novel food and pharmaceutical products.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251124"},"PeriodicalIF":1.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-11eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1092
Guanen Qiao, Pan Li, Meng Wang, Changjuan Li, Yanmei Wang, Shuanli Xin, Haitao Liu
{"title":"Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis.","authors":"Guanen Qiao, Pan Li, Meng Wang, Changjuan Li, Yanmei Wang, Shuanli Xin, Haitao Liu","doi":"10.1515/biol-2025-1092","DOIUrl":"10.1515/biol-2025-1092","url":null,"abstract":"<p><p>Long-term repeated exposure to various stimuli leads to chronic liver damage, inflammation, fibrosis, and eventually cirrhosis. Pyroptosis, a mode of inflammatory programed cell death, affects the progression of liver fibrosis/cirrhosis. However, current research on drugs targeting the pyroptosis pathway as a therapeutic strategy in liver fibrosis and cirrhosis remains limited. This review aims to explain the relationship between pyroptosis and liver cirrhosis and focuses on methods for the treatment of liver cirrhosis based on targeted pyroptosis. Here, 31 inhibitor drugs that target inflammasomes, gasdermin D, or caspases are discussed. Although the inhibitory effect of these drugs on pyroptosis is indisputable, their efficacy on cirrhosis needs a thorough investigation. Seventeen natural plant compounds that improve liver fibrosis/cirrhosis in cellular and animal models through targeting pyroptosis are also reviewed. In addition, stem cell replacement therapy and exosomes have broad application prospects in liver cirrhosis from the perspective of pyroptosis. In the future, the primary challenges will involve validating the efficacy of the aforementioned drugs in targeting pyroptosis for cirrhosis treatment using human liver organoids as well as determining their potential clinical application.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251092"},"PeriodicalIF":1.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Haplo-hematopoietic stem cell transplantation and immunoradiotherapy for severe aplastic anemia complicated with nasopharyngeal carcinoma: A case report.","authors":"Yanting Gao, Yun Zhang, Hong Wang, Jingjing Xiang, Xiangping Wu, Qinghong Yu","doi":"10.1515/biol-2025-1134","DOIUrl":"10.1515/biol-2025-1134","url":null,"abstract":"<p><p>Severe aplastic anemia (SAA) and nasopharyngeal carcinoma (NPC) are two different diseases and are life-threatening if left untreated. The co-occurrence of SAA and NPC is rare and presents a complex therapeutic paradox. This study reports a unique case of a patient diagnosed with both SAA and NPC. The patient initially underwent haploidentical hematopoietic stem cell transplantation (HSCT) to achieve rapid hematologic recovery, followed by nimotuzumab + radiotherapy for carcinoma treatment. This case suggests that sequential haploidentical HSCT and radiotherapy may represent a promising therapeutic strategy for patients with coexisting SAA and NPC.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251134"},"PeriodicalIF":1.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-11eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1139
Hongmei Yan, Gang Wang
{"title":"Modulation of the KEAP1-NRF2 pathway by Erianin: A novel approach to reduce psoriasiform inflammation and inflammatory signaling.","authors":"Hongmei Yan, Gang Wang","doi":"10.1515/biol-2025-1139","DOIUrl":"10.1515/biol-2025-1139","url":null,"abstract":"<p><p>Psoriasis is a chronic, immune-mediated skin condition marked by excessive cell growth and inflammation. Current therapies frequently have limitations, such as side effects and insufficient efficacy, emphasizing the need for safer, more effective options. Erianin (ERN), a naturally occurring bioactive molecule produced from <i>Dendrobium chrysotoxum</i>, has anti-inflammatory and antioxidant characteristics, although its therapeutic potential in psoriasis has not been fully investigated. The purpose of this investigation was to look into the protective benefits of ERN against psoriasis-like skin inflammation utilizing laboratory-based cell models and an imiquimod-induced psoriasis animal model. Human keratinocytes were subjected to pro-inflammatory cytokines <i>in vitro</i> to simulate psoriasis disease, and cell survival and proliferation were measured. <i>In vivo</i>, mice given ERN for 6 days demonstrated a significant decrease in skin thickness, inflammatory cell infiltration, and overall histopathological alterations. ERN reduced pro-inflammatory substances (IL-6, IL-17, IL-23, IL-1β), TNF-α, COX-2, and inducible nitric oxide synthase, while increasing anti-inflammatory cytokine IL-10 and antioxidant-related molecules. Additionally, ERN stimulated the Kelch-like ECH-associated protein 1- nuclear factor erythroid 2-related factor 2 signaling pathway, which is essential for cellular antioxidant defense. The results presented here demonstrate that ERN reduces psoriasis-like inflammation by modifying immunological responses and increasing antioxidant protection, pointing to its potential as a viable therapeutic agent for psoriasis treatment.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251139"},"PeriodicalIF":1.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Open Life SciencesPub Date : 2025-07-11eCollection Date: 2025-01-01DOI: 10.1515/biol-2025-1121
Xianglin Guo, Haiyan Qu, Xiaoxu Lin, Zhengxiang Guo, Han Xia
{"title":"Fabrication of zinc oxide nanoparticles using <i>Ruellia tuberosa</i> leaf extract induces apoptosis through P53 and STAT3 signalling pathways in prostate cancer cells.","authors":"Xianglin Guo, Haiyan Qu, Xiaoxu Lin, Zhengxiang Guo, Han Xia","doi":"10.1515/biol-2025-1121","DOIUrl":"10.1515/biol-2025-1121","url":null,"abstract":"<p><p>The use of plant-based medicines for the production of green nanomaterials represents a viable route for cancer treatment. In this study, we report a novel method for the biosynthesis of zinc oxide nanoparticles (ZnO NPs) using the leaf extract of <i>Ruellia tuberosa</i> L. a medicinal plant known for its therapeutic properties. The study aims to test and investigate the ability of these <i>R. tuberosa</i>-derived ZnO NPs (RT-ZnO NPs) to cause apoptosis in human prostate cancer (PC) cells and clarify their fundamental molecular pathways. The developed RT-ZnO NPs were analysed employing field emission scanning electron microscopy, which exhibited a spherical shape with a median particle size of 156.7 nm. The methylthiazolyldiphenyl-tetrazolium bromide experiment showed that RT-ZnO NPs demonstrated considerable cytotoxicity toward DU 145 PC cells, with an IC₅₀ value of 26.82 µg/mL, while demonstrating low toxicity against normal HPE-15 prostate epithelial cells. Furthermore, the molecular analysis demonstrated that the NPs boosted p53 expression while suppressing both total and phosphorylated STAT3, indicating that anticancer activity is mediated by the p53 and STAT3 signalling pathways. This study focuses on a green and cost-effective method for creating anticancer nanomaterials, with RT-ZnO NPs emerging as a potential alternative for PC therapy.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251121"},"PeriodicalIF":1.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}